Jazz Pharmaceuticals’ (JAZZ) “Buy” Rating Reaffirmed at HC Wainwright

Jazz Pharmaceuticals (NASDAQ:JAZZ)‘s stock had its “buy” rating reiterated by HC Wainwright in a report released on Friday, Benzinga reports. They presently have a $200.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 81.80% from the company’s previous close.

Other equities research analysts also recently issued research reports about the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $180.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, April 10th. Royal Bank of Canada reiterated an “outperform” rating and issued a $195.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, February 29th. JPMorgan Chase & Co. upped their price objective on shares of Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an “overweight” rating in a research report on Friday, March 22nd. Stifel Nicolaus lifted their target price on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. Finally, UBS Group cut their target price on Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating on the stock in a research note on Friday, March 1st. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $192.75.

Jazz Pharmaceuticals Stock Up 0.7 %

JAZZ stock traded up $0.72 during midday trading on Friday, reaching $110.01. 693,769 shares of the company’s stock traded hands, compared to its average volume of 597,957. Jazz Pharmaceuticals has a 52 week low of $103.01 and a 52 week high of $146.70. The company has a market cap of $6.94 billion, a price-to-earnings ratio of 22.68, a P/E/G ratio of 1.52 and a beta of 0.63. The firm’s fifty day moving average price is $116.44 and its 200-day moving average price is $121.02. The company has a quick ratio of 1.85, a current ratio of 2.27 and a debt-to-equity ratio of 1.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1.01 billion. Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. As a group, sell-side analysts forecast that Jazz Pharmaceuticals will post 16.24 earnings per share for the current fiscal year.

Insider Activity

In other Jazz Pharmaceuticals news, CFO Philip L. Johnson acquired 12,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, March 1st. The stock was acquired at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the purchase, the chief financial officer now owns 27,932 shares of the company’s stock, valued at $3,342,063.80. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Philip L. Johnson bought 12,000 shares of the business’s stock in a transaction on Friday, March 1st. The stock was acquired at an average price of $119.65 per share, for a total transaction of $1,435,800.00. Following the purchase, the chief financial officer now directly owns 27,932 shares in the company, valued at $3,342,063.80. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Patricia Carr sold 1,936 shares of the company’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the sale, the chief accounting officer now owns 8,364 shares in the company, valued at $1,000,668.96. The disclosure for this sale can be found here. Insiders own 4.40% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

Large investors have recently modified their holdings of the business. Baupost Group LLC MA raised its stake in Jazz Pharmaceuticals by 23.7% in the fourth quarter. Baupost Group LLC MA now owns 833,696 shares of the specialty pharmaceutical company’s stock valued at $102,545,000 after purchasing an additional 160,000 shares in the last quarter. International Assets Investment Management LLC bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at about $7,201,000. Desjardins Global Asset Management Inc. purchased a new stake in Jazz Pharmaceuticals during the 4th quarter valued at about $1,943,000. Kovack Advisors Inc. grew its position in Jazz Pharmaceuticals by 347.1% during the 4th quarter. Kovack Advisors Inc. now owns 29,971 shares of the specialty pharmaceutical company’s stock worth $3,686,000 after acquiring an additional 23,267 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale increased its stake in Jazz Pharmaceuticals by 94.2% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 91,540 shares of the specialty pharmaceutical company’s stock worth $11,210,000 after purchasing an additional 44,414 shares during the period. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.